Literature DB >> 16523255

[Carcinomas of the distal bile duct].

M Bahra1, J M Langrehr, P Neuhaus.   

Abstract

Malignancies of the biliary tree are classified into three groups according to location: intrahepatic, central (perihilar), and distal. Of all cholangiocarcinomas, 25% are located distally and can be subdivided into middle and lower bile duct carcinomas. Surgical approaches for achieving tumor-free resection margins (R0) are directly associated with the origin of the tumor. Intrahepatic and central cancers usually must be treated by liver surgery, whereas the majority of distal cholangiocarcinomas require pancreaticoduodenectomy. In case of a small, middle bile duct carcinoma, exclusive extrahepatic bile duct resection without pancreatic resection can be adequate. Five-year survival after radical resection is about 25%. Cancer of the distal bile duct has to be distinguished from ductal adenocarcinoma of the pancreas and carcinoma of the ampulla of Vater. Curative surgery is possible if the tumor is diagnosed early and radical resection is feasible. In this context, the role of an extended lymph node dissection remains unclear. To improve survival, future studies are needed to evaluate the role of novel adjuvant strategies (i.e., gemcitabine, capecitabine).

Entities:  

Mesh:

Year:  2006        PMID: 16523255     DOI: 10.1007/s00104-006-1160-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  27 in total

1.  Biliary tract cancer accompanied by anomalous junction of pancreaticobiliary ductal system in adults.

Authors:  K Tanaka; A Ikoma; N Hamada; S Nishida; J Kadono; A Taira
Journal:  Am J Surg       Date:  1998-03       Impact factor: 2.565

2.  Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience.

Authors:  M Kaya; P C de Groen; P Angulo; D M Nagorney; L L Gunderson; G J Gores; M G Haddock; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan--experience of a single institute.

Authors:  M Suzuki; M Unno; M Oikawa; K Endo; Y Katayose; S Matsuno
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

5.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

6.  Pathological aspects of cholangiocarcinoma.

Authors:  K Weinbren; S S Mutum
Journal:  J Pathol       Date:  1983-02       Impact factor: 7.996

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Carcinoid tumor of the biliary system. Case report and literature review.

Authors:  D L Jutte; R H Bell; I Penn; J Powers; J Kolinjivadi
Journal:  Dig Dis Sci       Date:  1987-07       Impact factor: 3.199

Review 9.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

Review 10.  Pathogenesis of carcinoma of the papilla of Vater.

Authors:  Hans-Peter Fischer; Hui Zhou
Journal:  J Hepatobiliary Pancreat Surg       Date:  2004
View more
  1 in total

Review 1.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.

Authors:  Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra
Journal:  Cancer Med       Date:  2015-12-09       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.